FOR IN VITRO AND PRE-CLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE
Cognitive

Selank 5mg

5mg anxiolytic cognitive research peptide

From€39.00
In Stock · Ships within 48h
Reviews coming soonBe among the first to share your research experience.
Download Certificate of Analysis
  • EU Dispatch
  • CoA Included — Every Batch
  • Discreet Packaging
Purity≥98% HPLC
FormLyophilised Powder
Storage2–8°C
OriginEuropean Stock
DispatchWithin 48h
SKUUL-SEL-5MG
≥98% PureHPLC verified
HPLC TestedDual identity check
EU DispatchShips within 48h
CoA Incl.Every batch
Research Profile

Why Selank Fascinates Researchers

Selank — systematic designation TP-7 — is a synthetic heptapeptide analogue of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of immunoglobulin G. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank extends the tuftsin sequence with a C-terminal Pro-Gly-Pro tripeptide that dramatically increases resistance to proteolytic degradation and enhances central nervous system penetration.

Tuftsin Analogue & Neuropeptide Architecture

Tuftsin (Thr-Lys-Pro-Arg) is an endogenous immunomodulatory tetrapeptide liberated from the Fc region of IgG by two enzymes: leukokinase and tuftsin endocarboxypeptidase. It exhibits immunostimulatory activity through macrophage and neutrophil activation. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) was designed to preserve tuftsin's core pharmacophore while adding a stability-conferring C-terminal extension. The Pro-Gly-Pro tripeptide provides resistance to aminopeptidases and endopeptidases that rapidly inactivate native tuftsin in vivo, extending the compound's pharmacokinetically active window and enabling CNS studies not feasible with the parent tetrapeptide.

GABA-A Modulation & Anxiolytic Research

The most extensively documented pharmacological property of Selank in preclinical literature is its anxiolytic activity mediated through the GABAergic system. Studies in rodent models have documented benzodiazepine-comparable anxiolytic effects in elevated plus-maze, open field, and fear conditioning paradigms, without the tolerance, dependence, or sedation observed with classical GABAergic anxiolytic drugs. The proposed mechanism involves potentiation of GABA-A receptor-mediated chloride conductance through an allosteric mechanism distinct from the benzodiazepine binding site. This selectivity profile has made Selank of interest as a pharmacological tool for dissecting GABAergic anxiety circuitry.

Neurotrophin Expression & Cognitive Research

A second pharmacological signature of Selank concerns its effects on neurotrophin expression. Studies in rodent brain tissue have documented upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) following Selank administration, particularly in hippocampal and frontal cortex regions. BDNF is a critical mediator of synaptic plasticity, long-term potentiation, and neuronal survival. The upregulation of this pathway — alongside documented improvements in learning and memory task performance in rodent models — has positioned Selank as a research tool in the field of neuropeptide cognitive pharmacology. Additionally, Selank modulates expression of interleukin-6, interferon-γ, and other cytokines, reflecting its tuftsin-derived immunomodulatory heritage.

This content is for informational purposes only and reflects the state of preclinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.

Manufacturing Standards

Our Quality Commitment

HPLC Verified

Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

≥98% Purity

Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.

Batch Traceability

Each vial is traceable to its synthesis batch, testing date, and analytical records.

Cold Chain Storage

European stock stored at optimal temperature from synthesis to dispatch.

48h EU Dispatch

Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.

CoA Included

Certificate of Analysis issued for every batch, available for download on request.

Download CoA for Selank 5mg
Peer-Reviewed Literature

Key Scientific Studies

Peer-reviewed research supporting Selank investigation.

[01]
Semenova TP, Kozlovskaya MM, Zakharova NM, Kozlovskii II. (2010) — Eksperimental'naia i Klinicheskaia Farmakologiia

“Behavioral and neurochemical properties of the peptide selank”

Pharmacological characterisation of Selank's behavioural and neurochemical profile in rodent models. The study documents anxiolytic activity in elevated plus-maze and open field paradigms, alongside effects on monoamine neurotransmitter systems. Neurochemical data show modulation of serotonergic and dopaminergic markers in limbic brain regions consistent with the compound's anxiolytic pharmacology.

View on PubMed
[02]
Uchakina ON, Uchakin PN, Mabondzo A, et al. (2008) — Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova

“Immunomodulatory effects of selank in patients with anxiety-asthenic disorders”

Clinical investigation examining Selank's immunomodulatory profile in patients with anxiety-related disorders. The study documents modulation of cytokine expression including IL-6, interferon-γ, and TNF-α, consistent with the tuftsin-derived immunopharmacological properties of the compound and providing human-relevant data on Selank's dual CNS-immune activity.

View on PubMed
[03]
Narkevich VB, Kozlovskaya MM, Valdman AV, Voronina TA. (1989) — Biulleten' Eksperimental'noi Biologii i Meditsiny

“Pharmacology of the peptide tuftsin and its analogues”

Foundational pharmacological study of tuftsin analogues establishing the structure-activity relationships relevant to Selank's design. The study identifies the key pharmacophore elements required for immunomodulatory and anxiolytic activity in the tuftsin peptide series, providing the mechanistic basis for the C-terminal Pro-Gly-Pro extension strategy used in Selank development.

View on PubMed

All studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.

Common Questions

Research FAQ

Answers to the most frequently asked questions about Selank.

Same Category

Similar Compounds

Other Cognitive research compounds from our catalogue.

Your Longevity Research Guide Awaits

Subscribe to receive new compound profiles, CoA updates, and curated research digests — delivered directly to your inbox.